Home Health Lilly trades at a premium to Ozempic-maker Novo as obesity drugs boom. Here’s why, analyst says

Lilly trades at a premium to Ozempic-maker Novo as obesity drugs boom. Here’s why, analyst says

0
Lilly trades at a premium to Ozempic-maker Novo as obesity drugs boom. Here’s why, analyst says

Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here